{"filing":{"accession_number":"0001193125-26-430980","cik":"0002029769","ticker":"OACCW","company_name":"Oaktree Acquisition Corp. III Life Sciences","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-23","primary_document":"d188348d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2029769/000119312526430980/d188348d8k.htm"},"events":[{"id":37744,"run_id":34785,"accession_number":"0001193125-26-430980","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Oaktree Acquisition Corp. III Life Sciences issued 4,798,758 Class A ordinary shares to the Sponsor upon conversion of Class B shares, with the shares explicitly stated as unregistered under the Securities Act of 1933 and issued in reliance on Section 3(a)(9) exemption. This unregistered equity issuance increases the Sponsor's Class A holdings and dilutes existing shareholders.","company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACCW","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42559,"accession_number":"0001193125-26-430980","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Oaktree Acquisition Corp. III Life Sciences issued 4,798,758 Class A ordinary shares to the Sponsor upon conversion of Class B shares, with the shares explicitly stated as unregistered under the Securities Act of 1933 and issued in reliance on Section 3(a)(9) exemption. This is a material unregistered equity issuance that increases the Sponsor's Class A holdings and dilutes existing shareholders, typical of SPAC sponsor conversions disclosed under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37745,"run_id":34785,"accession_number":"0001193125-26-430980","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Shareholders voted on October 23, 2026 to approve an Extension Amendment Proposal extending the business combination termination date from October 25, 2026 to November 25, 2026, with provisions for further monthly extensions up to May 25, 2027. The proposal passed with 17,956,072 votes in favor and 802,517 against, with 11.3 million Public Shares redeemed for approximately $122.4 million.","company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACCW","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42560,"accession_number":"0001193125-26-430980","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure concerns an amendment to OAC's articles of association approved by shareholders at an extraordinary general meeting on October 23, 2026. The amendment extends the business combination termination date from October 25, 2026 to November 25, 2026, with provisions for further monthly extensions up to May 25, 2027. While this is a governance matter involving shareholder-approved bylaw/articles amendments, it is routine administrative in nature—a common extension mechanism for blank-check companies—and does not materially affect the registrant's financial condition, operations, or investor risk profile beyond the procedural extension of the SPAC timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42561,"accession_number":"0001193125-26-430980","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of a shareholder vote held on October 23, 2026, where holders of OAC's ordinary shares voted on the Extension Amendment Proposal and an Adjournment Proposal. The filing provides specific vote tallies (17,956,072 for, 802,517 against, 0 abstain on the Extension Amendment Proposal), quorum information (76.3% of voting power present), and redemption activity (11.3 million Public Shares redeemed for approximately $122.4 million). This is a classic shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42559,"accession_number":"0001193125-26-430980","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Oaktree Acquisition Corp. III Life Sciences issued 4,798,758 Class A ordinary shares to the Sponsor upon conversion of Class B shares, with the shares explicitly stated as unregistered under the Securities Act of 1933 and issued in reliance on Section 3(a)(9) exemption. This is a material unregistered equity issuance that increases the Sponsor's Class A holdings and dilutes existing shareholders, typical of SPAC sponsor conversions disclosed under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACCW","filing_date":"2026-10-26"},{"id":42560,"accession_number":"0001193125-26-430980","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure concerns an amendment to OAC's articles of association approved by shareholders at an extraordinary general meeting on October 23, 2026. The amendment extends the business combination termination date from October 25, 2026 to November 25, 2026, with provisions for further monthly extensions up to May 25, 2027. While this is a governance matter involving shareholder-approved bylaw/articles amendments, it is routine administrative in nature—a common extension mechanism for blank-check companies—and does not materially affect the registrant's financial condition, operations, or investor risk profile beyond the procedural extension of the SPAC timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACCW","filing_date":"2026-10-26"},{"id":42561,"accession_number":"0001193125-26-430980","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of a shareholder vote held on October 23, 2026, where holders of OAC's ordinary shares voted on the Extension Amendment Proposal and an Adjournment Proposal. The filing provides specific vote tallies (17,956,072 for, 802,517 against, 0 abstain on the Extension Amendment Proposal), quorum information (76.3% of voting power present), and redemption activity (11.3 million Public Shares redeemed for approximately $122.4 million). This is a classic shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:06:25.807328+00:00","company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACCW","filing_date":"2026-10-26"}]}
